Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Array Biopharma Inc. (ARRY)
Lazard Annual Healthcare Conference Transcript
November 13, 2012 11:00 AM ET
Ron Squarer - Chief Executive Officer
Kevin Koch - President and Chief Scientific Officer
Ryan Martins - Lazard Capital Markets
Ryan Martins - Lazard Capital Markets
Previous Statements by ARRY
» Array Biopharma Management Discusses Submitted ASH Abstracts - (Transcript)
» Array BioPharma's CEO Discusses F1Q2013 Results - Earnings Call Transcript
» Array BioPharma's CEO Presents at UBS 2012 Global Life Sciences Conference (Transcript)
» Array BioPharma's CEO Presents at Morgan Stanley Healthcare Conference - Transcript
Good morning, everyone. It's good to see some familiar faces here in the room. We had a very very exciting week last week, and I'm glad to be here to be able to provide you an update, not just on the progress of the company but as you know we did raise additional money at the end of week last week to support the programs which we are very - continue to be excited about.
I am going to be making forward looking statements related to forecast for a full discussion of risks please see our 10-Q and 10K. As many of you know, we are still planning to have the possibility of entering with 5 products into pivotal trials next year, across our portfolio. We'd be reviewing what those area.
As of Monday last week we had another product going to Phase 2, and so we have a total now of 11 phase 2 programs 8 of which are currently partners. And partnerships have been an important of our strategy, and helped us to raise as much as $170 million in non-dilutive financing just in the last 2 to 3 years.
Our current partnered pipeline has associated with the $3.6 billion in potential milestones before royalties and may of our deals, do include double digit royalties. We ended the quarter, the last quarter call at $68 million in cash we raised an additional $66 million at the end of next year, the use of those proceeds were to invest in our wholly owned Hem/Onc portfolio which I've been talking to you about for some time.
But we do also have additional sources of non-dilutive financing through the partnership potential for our pain program, 797 as well as our asthma program which I'll touch on just a bit today, raise value really can be divided into three buckets on slide four at the MEK inhibitors, which historically have been a focus of investors and we saw progress on Thursday with Novartis committing to it's registration pathway for MEK162.
Increasingly we've been focusing with investors on the progress we're making on 614 and 520 both of which had abstracts published last week and we'll have sessions at ASH in December so we're making great progress on both of those. And of course, our existing partnerships we've quite a long tail that continues to make progress as well as two additional potential future sources of non-dilutive financing that I mentioned earlier.
If you look at the entire portfolio, on the right you'll see the dark-green on slide 5 in hashed green, those are our wholly owned programs, in the upper left corner you'll see the five potential phase 3 starts between now and the end of next year. And that we believe is going to drive very very significant value going forward. But as well our partnerships continue to progress as expected.
What I'm going to talk to a little bit about is the news that Novartis committed to moving forward not only in NRAS Melanoma but also in BRAF, so that's 20% and 40% of melanoma respectively.
Talk to you a little bit about the Selumetinib/MEK update at ESMO and some other progress there. ASH abstracts are out, I've listed them here. But they relate to the single-agent beta in heavily pre-treated patients but also what benefit dex showed the use of a bio selection marker and additionally as bit of an update on Carfilzomib with 614 the focus is more on PK and PD.
As someone told me to talk about the Pain program which you may recall in over the summer we presented a positive Phase II study statistically significant versus placebo on top of NSAID and comparable to the oxycodone arm. This abstract provides a little bit more detail on that efficacy data over time. And it also points for the first time to disease modification markers associated with bone and cartilage degradation. So in that abstract which is actually up and I think it was presented today.
We saw decreases of 10% and 38% respectively in COMP and CTX-1 at week 4 and those are as I mentioned biomarkers related to bone and cartilage, also this would be an unprecedented results where you've got a very active analgesic that also appears to have disease modifying properties and look forward to seeing that profile emerge thorugh a partner.
We're going to focus today a bit on our wholly-owned Hem programs, which of course we've put a lot of new information out. I'll start with the opportunity in MDS. A very large disease, about a 153,000 patients and these patients typically suffer from multiple cytopenias. The population that we're focusing on low-risk int-1 as you can see on the left represents a majority of patients. They tend not to have blast counts or high-blast counts for per ten, they just do suffer from cytopenias and ultimately tend to pass from the complications of the cytopenias or the treatment supportive care, treatment for those.